Cumulus Neuroscience has tapped digital health expert Dr. Aman Bhatti as CEO. He joins the company from AliveCor BioPharma, where he served as SVP.
“Neurological disorders are a global health issue, and digital biomarkers – which require integrated, multi-domain assessment technologies – are key to supporting faster drug development, disease diagnosis, and therapeutic solutions,” said Cumulus co-founder and executive chair Ruth McKernan, PhD in a statement. “Dr. Bhatti’s proven track record of implementing strategies that achieve significant revenue growth in both the biopharma and healthcare industries, combined with his unique understanding of healthcare system priorities and patient, physician, biopharma and payer needs, makes him the ideal match to lead Cumulus in its next chapter.”
Prior to his AliveCor tenure, Bhatti held leadership roles at Sanofi, GSK and Novartis. Consumer brands he helped launch or grow include Mucinex, Theraflu, Flonase and Nicorette.
“My passion is finding the intersection of technological innovation, scientific understanding, and patient care, to make better health possible — and Cumulus technology is poised to do just that, by enabling better understanding and faster identification of neurodegenerative and neuropsychiatric diseases,” Bhatti added in the statement.